Last edition
News about "Event-free survival"
AstraZeneca's Imfinzi Combo Gets US Priority Review for MIBC
AstraZeneca’s Imfinzi and enfortumab vedotin combination has received US FDA Priority Review based on positive Phase 3 VOLGA results in muscle-invasive bladder cancer.
Event-Free Survival | 28/09/2026 | By News Bureau
Merck Gets Positive EU Opinion for Keytruda-Padcev in MIBC
Merck’s Keytruda plus Padcev receives a positive CHMP opinion for perioperative treatment of adults with resectable muscle-invasive bladder cancer, with the EC set to review the recommendation.
Event-free Survival | 19/09/2026 | By News Bureau
Ultomiris Misses Phase 3 Endpoint in Post-Transplant TMA Trial
AstraZeneca shares a phase 3 update on Ultomiris for Haematopoietic Stem Cell Transplant (HSCT)-TMA, showing a trend toward clinical benefit in adults and adolescents as regulatory discussions continue.
Event-free Survival | 28/07/2026 | By News Bureau | 156
Philogen Resubmits EMA Marketing Application for Melanoma Therapy Nidlegy with Updated Phase 3 Data
Philogen has resubmitted its EMA marketing application for investigational melanoma therapy Nidlegy, supported by updated Phase 3 clinical data demonstrating reduced risk of relapse or death and an extended patient follow-up period.
Event-Free Survival | 28/07/2026 | By News Bureau | 152
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Event-free Survival | 15/05/2026 | By News Bureau | 142
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy